HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutraceutix name change

This article was originally published in The Tan Sheet

Executive Summary

Shareholders will be asked to approve company name change to SCOLR at annual meeting July 2. SCOLR, pronounced "scholar," stands for Self Correcting Oral Linear Release, which is the technology behind Nutraceutix' CDT drug delivery platform. In proxy materials filed with SEC, firm says new name better reflects "shift in focus from its nutraceutical business to developing its drug delivery technology." In March, Nutraceutix licensed to Archer Daniels Midland exclusive, worldwide rights to market ingredients incorporating CDT technology to supplement manufacturers (1"The Tan Sheet" April 8, 2002, p. 13)...

You may also be interested in...



Nutraceutix’ new moniker

Name change to SCOLR approved by shareholders July 2. New name, which stands for Self Correcting Oral Linear Release, is aimed at better reflecting Redmond, Wash.-based firm's shift in focus from the nutraceutical business to drug delivery technology development (1"The Tan Sheet" June 3, 2002, In Brief)...

ADM Novasoy Daily Dose Provides “Steady Delivery” Of Soy Isoflavones

Archer Daniels Midland will roll out Novasoy Daily Dose, incorporating Nutraceutix's patented Controlled Delivery Technology (CDT), to the dietary supplement industry over the next six months

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

Topics

UsernamePublicRestriction

Register

RS130038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel